The immune response to a meningococcal 200 kDa surface exposed protein following carriage and disease

Raymond Borrow*, Andrew Fox, D. M. Jones

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Considerable efforts are being made in the search for suitable candidates for an effective serogroup B meningococcal vaccine, but with limited success. We have identified a novel, high molecular weight antigen of approximately 200 kDa. The antigen was expressed during invasive disease as 100% of convalescent case sera contained antibody compared with approximately 50% of carriers. Many clinical isolates did not appear to express the 200 kDa antigen, but corresponding sera contained antibody, indicating in vivo expression. Antibody to this antigen cross-reacted with meningococci of diverse phenotypes. Further investigation of this antigen is required to determine its potential as a future vaccine component.

Original languageEnglish
Pages (from-to)179-184
Number of pages6
JournalSerodiagnosis and Immunotherapy in Infectious Disease
Volume8
Issue number3-4
DOIs
Publication statusPublished - Jan 1997
Externally publishedYes

Bibliographical note

Funding Information:
This study was funded by the Medical Research Council. UK. grant number SPG 911663 1.

Keywords

  • High molecular weight protein
  • Meningococcal
  • Vaccine

Fingerprint

Dive into the research topics of 'The immune response to a meningococcal 200 kDa surface exposed protein following carriage and disease'. Together they form a unique fingerprint.

Cite this